Table 1.
A list of recombinant protein antigens produced in P. pastoris for use in the development of human subunit vaccines.
| Pathogen/Antigen | Yield (mg/L) | Mode of expression* | Efficacy | Reference |
|---|---|---|---|---|
| Epstein-Barr virus envelope glycoprotein gp350 | 120.34 | S | Recombinant gp3501–443(codons 1–443) demonstrated strong immunogenicity | 63 |
| Epstein-Barr virus nuclear antigen 1 (EBNA1) | 210.53 | S | Recombinant E1ΔGA (codons 390–641) induced both humoral and cellular immune responses | 65 |
| Dengue virus (DENV-3) envelope domain-III (EDIII) | 187 | S | The purified EDIII antigen could efficiently induce neutralizing antibodies | 68 |
| Avian influenza virus (H5N1) neuraminidase (NA) | 2 | S | Recombinant NA elicited significant humoral responses in mice | 70 |
| Japanese encephalitis virus envelope (E) protein | 19 | S | Recombinant E protein could induce protective immunity in vaccinated mice | 71 |
| Human enterovirus 71 capsid protein VP1 | 500 | S | Recombinant VP1 could protect neonatal mice from lethal virus challenge | 73 |
| Dengue virus (DENV-3) envelope ectodomain | 15 | I | DENV-3 E-based VLPs elicited predominantly neutralizing antibodies | 74 |
| Human papillomavirus type 16 major capsid protein L1 | 13.4-14.2 | I/S | HPV VLPs were successfully produced | 76,77 |
| Coxsackievirus A16 P1 polypeptide and 3CD protease | 8.3 | I | CA16 VLPs induced high-titer serum antibodies and conferred complete protection against lethal virus challenge in neonatal mice | 79 |
| Human enterovirus 71 P1 polypeptide and 3CD protease | 150 | I | EV71 VLPs induced neutralizing antibodies and provided protection against lethal virus infection in neonatal mice | 80 |
| Hepatitis B virus surface antigen (HBsAg) | 50 | I | HBsAg-based VLPs were proven to be superior to currently licensed HBV vaccine (Engerix-B®) | 81 |
*
I: Intracellular, S: Secreted.